Literature DB >> 10212000

Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma.

Y K Kang1, W H Kim, H W Lee, H K Lee, Y I Kim.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is the second most common malignant tumor in liver; however, the carcinogenic mechanism of ICC is poorly understood. To analyze the molecular carcinogenesis of ICC, we examined the alterations of the p53, APC, and K-ras genes in 40 surgically resected ICC cases. The single-strand conformation polymorphism/sequencing revealed a p53 mutation in 12 cases (30%). An immunohistochemical overexpression of the p53 gene was detected in 10 cases (25%). The PCR/RFLP showed loss of heterozygosity of APC in 4 of 17 informative cases (23.5%). And the PCR/RFLP assay of K-ras codon 12 revealed the mutation in nine cases (22.5%). Twenty-one cases (52.5%) showed an alteration of at least one of the examined genes, and six (15%) carried an abnormality in more than two genes. The analysis of the clinicopathologic findings disclosed a significant relationship between the genetic alteration and gross type of the tumor: the p53 mutation was prominent in the ICC of mass-forming type, and K-ras mutation occurred more frequently in the ICC of periductal extension type (p < 0.05). These data suggest that each of the examined genes is involved in the development of ICC and that the p53 and K-ras mutation may play a role in the tumor growth pattern.

Entities:  

Mesh:

Year:  1999        PMID: 10212000

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  17 in total

1.  Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.

Authors:  Christos G Tsokos; Gregor Krings; Funda Yilmaz; Linda D Ferrell; Ryan M Gill
Journal:  Hum Pathol       Date:  2016-07-07       Impact factor: 3.466

Review 2.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

3.  Genetic alterations and growth pattern in biliary duct carcinomas: loss of heterozygosity at chromosome 5q bears a close relation with polypoid growth.

Authors:  E Hidaka; A Yanagisawa; M Seki; T Setoguchi; Y Kato
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 4.  The cholangiocyte primary cilium in health and disease.

Authors:  Adrian P Mansini; Estanislao Peixoto; Kristen M Thelen; Cesar Gaspari; Sujeong Jin; Sergio A Gradilone
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-06-15       Impact factor: 5.187

5.  Extensive biliary intraepithelial neoplasia (BilIN) and multifocal early intrahepatic cholangiocarcinoma in non-biliary cirrhosis.

Authors:  Anne-Laure Rougemont; Muriel Genevay; Thomas A McKee; Magali Gremaud; Gilles Mentha; Laura Rubbia-Brandt
Journal:  Virchows Arch       Date:  2010-04-29       Impact factor: 4.064

6.  Aberrant DNA methylation profile in cholangiocarcinoma.

Authors:  Li Huang; Gabriel Frampton; Li-Jian Liang; Sharon Demorrow
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

7.  Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse.

Authors:  Corey M Carlson; Joel L Frandsen; Nicole Kirchhof; R Scott McIvor; David A Largaespada
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-14       Impact factor: 11.205

8.  New insights on cholangiocarcinoma.

Authors:  Manuela Gatto; Domenico Alvaro
Journal:  World J Gastrointest Oncol       Date:  2010-03-15

Review 9.  Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets.

Authors:  Dalbir S Sandhu; Abdirashid M Shire; Lewis R Roberts
Journal:  Liver Int       Date:  2007-11-21       Impact factor: 5.828

10.  Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization.

Authors:  Ji-Young Lee; Young-Nyun Park; Kyung-Ok Uhm; Soo-Yeun Park; Sun-Hwa Park
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.